CClinicalTrials.gg
Status unknownNCT02198755Updated Jul 24, 2014

Detection of Osteomyelitis Using High Resolution Ultrasound

An interventional study of Hitachi-Aloka Noblus ultrasound scanner and Magnetic Resonance Imaging (MRI) in Chronic Osteomyelitis, sponsored by Calvary Hospital, Bronx, NY. Status unknown at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-07-24.

Sponsored by Calvary Hospital, Bronx, NY · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jul 2014), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to establish the sensitivity of HRUS as compared to MRI for the diagnosis of osteomyelitis in chronic wound patients; and to determine the specificity of HRUS as compared to pathologic and microbiologic studies of bone biopsy tissues.

02

Conditions studied

  • Chronic Osteomyelitis

Browse trials for

Keywords

  • high resolution ultrasound
  • osteomyelitis
03

In context

Osteomyelitis

113 studies on the registry are indexed under Osteomyelitis; 33 are open to participants now.

This study's planned enrollment of 100 is above the median of 65 across 58 interventional studies indexed under Osteomyelitis.

Browse Osteomyelitis studies →

Lead sponsor

Calvary Hospital, Bronx, NY is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patient may be of any race and between 18-85 years of age.
  2. Patient has a current diagnosis of a chronic ulcer with suspected osteomyelitis.
  3. Patient's ulcer may be due to any etiology including but not limited to diabetes, trauma, neuropathic, pressure, venous, arterial, and inflammatory.
  4. Patient's ulcer may extend through the dermis and into subcutaneous tissue (granulation tissue may be present), and may include exposure of muscle, tendon, bone, or joint capsule.
  5. Patient's ulcer is suspected of causing a bone infection.
  6. Patient's ulcer may be of any size.
  7. Patient's wound may present with non-viable tissue.
  8. Patient circulation to the wound should be evaluated and treated using normal protocol.
  9. Patient's diabetes is under control as determined by the Investigator. Patients must have an HbA1c value less than 13.0%. Those patients whose glucose level is not deemed to be in control should be referred to their primary physician for treatment of the hyperglycemia.
  10. Patient and caregiver are willing to participate in the clinical study and comply with the follow-up regimen.
  11. Patient or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment.
  12. If patient is capable of childbirth, she is using medically accepted means of birth control, and she tests negative on a serum pregnancy test.
  13. Active localized acute wound infection or cellulitis: Subject may be considered for study enrollment after the signs and symptoms of acute infection have resolved.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a condition where an MRI is contraindicated

    • Metallic fragments, clips or devices in the brain, eye, spinal canal, etc.: (Plain radiography is sufficient for screening
    • Magnetically activated implanted devices:

    Cardiac pacemakers, insulin pumps, neuro¬stim¬u¬lators, cochlear implants, etc. may be de-programmed.

    • Non-graphite spinal cord tongs: Graphite tongs are compatible.
    • Thermodilution Swan-Ganz catheter: Local heating can result. If unenhanced MRI is likely to provide sufficient information, gadolinium should not be administered to these patients. If, after review of clinical indications, gadolinium enhancement is judged to be important for diagnosis, the lowest effective dose of contrast agent should be used.
  2. In subjects where gadolinium enhancement MRI is planned then the following exclusion criteria apply:

    • Subject is allergic to contrast materials or cannot tolerate gadolinium
    • Subject is at risk of nephrogenic systemic fibrosis (NSF) or has severe renal failure (as determined by the investigator)
  3. Patient must not be pregnant.
  4. Patient has any condition(s) that seriously compromises the patient's ability to complete this study.
  5. Patient with recent surgical debridement of the bone in and around the ulcer site.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    High Resolution Ultrasound

    High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner

    Device: Hitachi-Aloka Noblus ultrasound scanner

  • Active comparator
    Magnetic Resonance Imaging (MRI)

    Magnetic Resonance Imaging (MRI)

    Device: Magnetic Resonance Imaging (MRI)

Interventions

  • DeviceHitachi-Aloka Noblus ultrasound scanner

    High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer

  • DeviceMagnetic Resonance Imaging (MRI)

    MRI with or without contrast

06

What researchers measure

Primary outcomes

  1. Percent sensitivity and specificity of HRUS as compared to MRI and bone biopsy

    Time frame: at 3 weeks

07

Study locations

1 site
  • Center for Curative and Palliative Wound Care, Calvary Hospital
    Bronx, New York 10461, United States
    • Tashara Smith, BS · Contact · tsmith@calvaryhospital.org · 718-518-2577
    • Martin Wendeken, DPM, RN · Sub investigator
    • Oscar M Alvarez, PhD · Principal investigator
    • Lee Markowitz, DPM · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02198755
Lead sponsor
Calvary Hospital, Bronx, NY
Responsible party
Oscar M. Alvarez, PhD (Director, Center for Curative and Palliative Wound Care, Calvary Hospital, Bronx, NY) — Principal investigator
First posted
Jul 24, 2014
Start date
Dec 2014
Primary completion
Dec 2015 (estimated)
Completion
Jun 2016 (estimated)
Last update
Jul 24, 2014

Study contacts

Oscar M Alvarez, PhD
principal investigator · Director, Wound Care Center, Calvary Hospital
Martin Wendelken, DPM, RN
study director · Staff Podiatrist, Wound Care Center, Calvary Hospital, Bronx, NY

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion